AU2017348172B2 - Cyclic peptide tyrosine tyrosine compounds as modulators of Neuropeptide Y receptors - Google Patents

Cyclic peptide tyrosine tyrosine compounds as modulators of Neuropeptide Y receptors Download PDF

Info

Publication number
AU2017348172B2
AU2017348172B2 AU2017348172A AU2017348172A AU2017348172B2 AU 2017348172 B2 AU2017348172 B2 AU 2017348172B2 AU 2017348172 A AU2017348172 A AU 2017348172A AU 2017348172 A AU2017348172 A AU 2017348172A AU 2017348172 B2 AU2017348172 B2 AU 2017348172B2
Authority
AU
Australia
Prior art keywords
fmoc
compound
acid
peptide
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017348172A
Other languages
English (en)
Other versions
AU2017348172A1 (en
Inventor
Martin A. CASE
Mark Macielag
Raymond J. Patch
Mark Wall
Rui Zhang
Yue-Mei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62020814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017348172(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2017348172A1 publication Critical patent/AU2017348172A1/en
Assigned to JANSSEN PHARMACEUTICA NV reassignment JANSSEN PHARMACEUTICA NV Amend patent request/document other than specification (104) Assignors: JANSSEN PHARMACEUTICA NV, MARK MACIELAG
Application granted granted Critical
Publication of AU2017348172B2 publication Critical patent/AU2017348172B2/en
Priority to AU2022200089A priority Critical patent/AU2022200089B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017348172A 2016-10-27 2017-10-26 Cyclic peptide tyrosine tyrosine compounds as modulators of Neuropeptide Y receptors Active AU2017348172B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200089A AU2022200089B2 (en) 2016-10-27 2022-01-07 Cyclic peptide tyrosine tyrosine compounds as modulators of Neuropeptide Y receptors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662413613P 2016-10-27 2016-10-27
US201662413586P 2016-10-27 2016-10-27
US62/413,586 2016-10-27
US62/413,613 2016-10-27
PCT/US2017/058451 WO2018081367A1 (en) 2016-10-27 2017-10-26 Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200089A Division AU2022200089B2 (en) 2016-10-27 2022-01-07 Cyclic peptide tyrosine tyrosine compounds as modulators of Neuropeptide Y receptors

Publications (2)

Publication Number Publication Date
AU2017348172A1 AU2017348172A1 (en) 2019-04-18
AU2017348172B2 true AU2017348172B2 (en) 2021-10-07

Family

ID=62020814

Family Applications (6)

Application Number Title Priority Date Filing Date
AU2017348172A Active AU2017348172B2 (en) 2016-10-27 2017-10-26 Cyclic peptide tyrosine tyrosine compounds as modulators of Neuropeptide Y receptors
AU2017348175A Active AU2017348175B2 (en) 2016-10-27 2017-10-26 Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
AU2017348180A Active AU2017348180B2 (en) 2016-10-27 2017-10-26 Immunoglobulins and uses thereof
AU2021269420A Active AU2021269420B2 (en) 2016-10-27 2021-11-19 Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
AU2022200089A Active AU2022200089B2 (en) 2016-10-27 2022-01-07 Cyclic peptide tyrosine tyrosine compounds as modulators of Neuropeptide Y receptors
AU2025201677A Pending AU2025201677A1 (en) 2016-10-27 2025-03-07 Immunoglobulins and uses thereof

Family Applications After (5)

Application Number Title Priority Date Filing Date
AU2017348175A Active AU2017348175B2 (en) 2016-10-27 2017-10-26 Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
AU2017348180A Active AU2017348180B2 (en) 2016-10-27 2017-10-26 Immunoglobulins and uses thereof
AU2021269420A Active AU2021269420B2 (en) 2016-10-27 2021-11-19 Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
AU2022200089A Active AU2022200089B2 (en) 2016-10-27 2022-01-07 Cyclic peptide tyrosine tyrosine compounds as modulators of Neuropeptide Y receptors
AU2025201677A Pending AU2025201677A1 (en) 2016-10-27 2025-03-07 Immunoglobulins and uses thereof

Country Status (39)

Country Link
US (15) US10428134B2 (cg-RX-API-DMAC10.html)
EP (5) EP3534928A4 (cg-RX-API-DMAC10.html)
JP (8) JP7231539B2 (cg-RX-API-DMAC10.html)
KR (6) KR102704251B1 (cg-RX-API-DMAC10.html)
CN (4) CN110099692B (cg-RX-API-DMAC10.html)
AU (6) AU2017348172B2 (cg-RX-API-DMAC10.html)
BR (3) BR112019008351A2 (cg-RX-API-DMAC10.html)
CA (3) CA3041674A1 (cg-RX-API-DMAC10.html)
CL (3) CL2019001110A1 (cg-RX-API-DMAC10.html)
CO (3) CO2019003938A2 (cg-RX-API-DMAC10.html)
CR (3) CR20190208A (cg-RX-API-DMAC10.html)
CY (1) CY1124732T1 (cg-RX-API-DMAC10.html)
DK (1) DK3532486T3 (cg-RX-API-DMAC10.html)
DO (3) DOP2019000107A (cg-RX-API-DMAC10.html)
EC (3) ECSP19029942A (cg-RX-API-DMAC10.html)
ES (2) ES3025907T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20211626T1 (cg-RX-API-DMAC10.html)
HU (1) HUE056442T2 (cg-RX-API-DMAC10.html)
IL (6) IL266202B2 (cg-RX-API-DMAC10.html)
JO (3) JOP20190095A1 (cg-RX-API-DMAC10.html)
LT (1) LT3532486T (cg-RX-API-DMAC10.html)
MA (3) MA46665B1 (cg-RX-API-DMAC10.html)
MD (1) MD3532486T2 (cg-RX-API-DMAC10.html)
MX (6) MX2019004952A (cg-RX-API-DMAC10.html)
MY (2) MY199449A (cg-RX-API-DMAC10.html)
NI (2) NI201900043A (cg-RX-API-DMAC10.html)
PE (3) PE20191079A1 (cg-RX-API-DMAC10.html)
PH (3) PH12019500723A1 (cg-RX-API-DMAC10.html)
PL (1) PL3532486T3 (cg-RX-API-DMAC10.html)
PT (1) PT3532486T (cg-RX-API-DMAC10.html)
RS (1) RS62677B1 (cg-RX-API-DMAC10.html)
SA (3) SA519401646B1 (cg-RX-API-DMAC10.html)
SG (4) SG11201902873RA (cg-RX-API-DMAC10.html)
SI (1) SI3532486T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202100647T1 (cg-RX-API-DMAC10.html)
TW (4) TWI794189B (cg-RX-API-DMAC10.html)
UY (3) UY37456A (cg-RX-API-DMAC10.html)
WO (3) WO2018081370A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202200648B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
US11780900B2 (en) 2018-04-25 2023-10-10 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TWI847981B (zh) * 2018-04-25 2024-07-11 比利時商健生藥品公司 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
WO2020188510A2 (en) * 2019-03-19 2020-09-24 Enzene Biosciences Limited Process of preparation of glucagon-like peptide-1 (glp-1) receptor agonists and their analogs
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
WO2020262590A1 (ja) * 2019-06-28 2020-12-30 味の素株式会社 環状ペプチドの製造方法
KR20220100925A (ko) 2019-11-11 2022-07-18 베링거 인겔하임 인터내셔날 게엠베하 Npy2 수용체 작용제
EP4069726A4 (en) * 2019-12-04 2024-03-20 The Scripps Research Institute GLP2 RECEPTOR AGONISTS AND METHOD OF USE
CN111494606B (zh) * 2020-04-24 2021-12-14 广州医科大学 神经肽y的新应用
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
EP4288078A4 (en) * 2021-02-03 2024-12-11 Sun Pharmaceutical Industries Ltd READY-TO-USE OXYTOCIN DOSAGE FORM
CN115073556A (zh) * 2021-03-12 2022-09-20 上海天慈生命科学发展有限公司 一类阿片/神经肽ff受体多靶点环肽分子及其制备和应用
BR112023026286A2 (pt) * 2021-06-14 2024-03-05 Darbix Llc Agonistas do receptor de glp-1 com propriedades farmacológicas e de liberação de fármacos melhoradas
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
WO2023097363A1 (en) * 2021-11-30 2023-06-08 Garvan Institute Of Medical Research Improved binding proteins and uses thereof
CN115028551B (zh) * 2022-07-15 2024-01-05 成都普康生物科技有限公司 一种叠氮-九甘醇-丙酸的制备方法
CN116098987A (zh) * 2023-02-09 2023-05-12 华东医院 甘丙肽在制备治疗非酒精性脂肪性肝病药物中的用途
CN117924142A (zh) * 2024-01-19 2024-04-26 成都普康生物科技有限公司 司美格鲁肽侧链的液相合成方法和司美格鲁肽的合成方法
WO2025252023A1 (en) * 2024-06-03 2025-12-11 Fortvita Biologics Inc. Modulators for gipr, glp1r and/or gcgr and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089789A2 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
US20070244041A1 (en) * 2004-02-23 2007-10-18 Reoscience A/S Peptide Yy Analogues

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2434149A1 (fr) 1978-06-22 1980-03-21 Parcor Nouveaux derives de la l-cysteine
US5393669A (en) 1993-02-05 1995-02-28 Martek Biosciences Corp. Compositions and methods for protein structural determinations
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP2471810A1 (en) 2006-02-22 2012-07-04 Merck Sharp & Dohme Corporation Oxyntomodulin derivatives
AU2007227202B2 (en) * 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
BRPI0718225A2 (pt) 2006-10-05 2013-11-12 Centocor Ortho Biotech Inc Antagonistas de ccr2 para tratamento de fibrose
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
BRPI0921640A2 (pt) 2008-11-04 2019-09-24 Janssen Pharmaceutica Nv agonistas peptídicos do crhr2 e usos do mesmo
BRPI0921230A2 (pt) * 2008-11-05 2018-10-30 Hoffmann La Roche agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
CN102573888A (zh) 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
KR20130018410A (ko) * 2010-03-26 2013-02-21 노보 노르디스크 에이/에스 새로운 글루카곤 유사체
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
US8906649B2 (en) * 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
EP2621950A4 (en) 2010-09-27 2015-09-02 Janssen Biotech Inc ANTIBODIES FOR BINDING HUMAN COLLAGEN II
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CA2825778A1 (en) * 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
TWI601744B (zh) * 2011-06-17 2017-10-11 韓美科學股份有限公司 包含調酸素與免疫球蛋白片段之複合物及其用途
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
SG11201407420RA (en) * 2012-07-04 2015-02-27 Hoffmann La Roche Covalently linked antigen-antibody conjugates
EA039082B1 (ru) * 2012-11-06 2021-12-01 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
SG11201504920SA (en) 2012-12-27 2015-07-30 Sanofi Sa Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
EP2943512A4 (en) 2013-01-11 2016-06-01 California Inst Biomedical Res BOVINE FUSION ANTIBODY
EP2992008B1 (en) 2013-05-02 2019-04-10 GlaxoSmithKline Intellectual Property Development Limited Therapeutic peptides
ES2719584T3 (es) * 2014-04-11 2019-07-11 Medimmune Llc Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
BR112018008908A2 (pt) * 2015-11-02 2018-11-27 Janssen Pharmaceutica Nv anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TWI847981B (zh) * 2018-04-25 2024-07-11 比利時商健生藥品公司 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244041A1 (en) * 2004-02-23 2007-10-18 Reoscience A/S Peptide Yy Analogues
WO2005089789A2 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions

Also Published As

Publication number Publication date
CN110099692A (zh) 2019-08-06
TW201827456A (zh) 2018-08-01
WO2018081375A1 (en) 2018-05-03
EP3988123A1 (en) 2022-04-27
NI201900044A (es) 2019-09-09
MA46672A (fr) 2019-09-04
CR20190209A (es) 2019-08-21
IL266204A (en) 2019-06-30
MY199666A (en) 2023-11-15
WO2018081370A1 (en) 2018-05-03
PL3532486T3 (pl) 2022-01-31
PH12019500906A1 (en) 2020-01-20
MD3532486T2 (ro) 2022-01-31
JP7231539B2 (ja) 2023-03-01
JP7090077B2 (ja) 2022-06-23
AU2025201677A1 (en) 2025-03-27
TW202304972A (zh) 2023-02-01
EP3532092A4 (en) 2020-07-01
PT3532486T (pt) 2021-11-19
PE20190916A1 (es) 2019-06-26
EP4574166A3 (en) 2025-09-03
UY37456A (es) 2018-04-30
AU2017348180A1 (en) 2019-04-18
US11767354B2 (en) 2023-09-26
US20180117170A1 (en) 2018-05-03
HRP20211626T1 (hr) 2022-02-04
SG11201902879SA (en) 2019-05-30
AU2017348180B2 (en) 2024-12-12
KR20240046621A (ko) 2024-04-09
IL266206B2 (en) 2025-01-01
IL314935A (en) 2024-10-01
CA3041672A1 (en) 2018-05-03
SG10202107777XA (en) 2021-08-30
JP2024020405A (ja) 2024-02-14
US20190263879A1 (en) 2019-08-29
IL266202A (en) 2019-06-30
BR112019008500A2 (pt) 2019-07-09
EP3988123C0 (en) 2025-02-26
US10968264B2 (en) 2021-04-06
WO2018081367A1 (en) 2018-05-03
KR20240046290A (ko) 2024-04-08
MX2024001845A (es) 2024-03-06
PH12019500723A1 (en) 2019-11-11
US20240018208A1 (en) 2024-01-18
MX2019004954A (es) 2019-06-24
IL266204B1 (en) 2024-09-01
MX2023014354A (es) 2023-12-15
HUE056442T2 (hu) 2022-02-28
US20190298849A1 (en) 2019-10-03
US11401315B2 (en) 2022-08-02
TW201827081A (zh) 2018-08-01
CL2019001136A1 (es) 2019-07-05
JP2022137031A (ja) 2022-09-21
EP4574166A2 (en) 2025-06-25
US20210163566A1 (en) 2021-06-03
JOP20190096B1 (ar) 2023-09-17
MA46665A (fr) 2019-09-04
SI3532486T1 (sl) 2021-12-31
TWI781118B (zh) 2022-10-21
US10968265B2 (en) 2021-04-06
CN110036022A (zh) 2019-07-19
US10858413B2 (en) 2020-12-08
CO2019004203A2 (es) 2019-05-10
US10428134B2 (en) 2019-10-01
UY37457A (es) 2018-04-30
SG11201902873RA (en) 2019-05-30
AU2022200089B2 (en) 2023-11-16
MA46718A (fr) 2019-09-11
BR112019008417A2 (pt) 2019-09-03
JP2023012467A (ja) 2023-01-25
TWI773699B (zh) 2022-08-11
IL266206B1 (en) 2024-09-01
JP7724196B2 (ja) 2025-08-15
RS62677B1 (sr) 2021-12-31
DOP2019000106A (es) 2019-09-30
JP2019534283A (ja) 2019-11-28
EP3532486B8 (en) 2022-01-12
CO2019003938A2 (es) 2019-04-30
US10640544B2 (en) 2020-05-05
AU2017348175A1 (en) 2019-04-18
KR102704251B1 (ko) 2024-09-06
SG11201902886SA (en) 2019-05-30
KR20190072616A (ko) 2019-06-25
KR102653376B1 (ko) 2024-04-02
ZA202200648B (en) 2024-02-28
BR112019008351A2 (pt) 2019-10-01
CN118085061A (zh) 2024-05-28
CL2019001110A1 (es) 2019-07-05
TW201829455A (zh) 2018-08-16
US20180125998A1 (en) 2018-05-10
ES2897480T3 (es) 2022-03-01
IL266204B2 (en) 2025-01-01
AU2021269420A1 (en) 2021-12-16
US20190345214A1 (en) 2019-11-14
KR20190073492A (ko) 2019-06-26
US12134636B2 (en) 2024-11-05
DK3532486T3 (da) 2021-10-18
EP3534928A4 (en) 2020-08-12
MY199449A (en) 2023-10-30
NZ752576A (en) 2025-09-26
CO2019004186A2 (es) 2019-05-10
AU2022200089A1 (en) 2022-02-03
IL266202B1 (en) 2023-05-01
SA519401642B1 (ar) 2022-03-07
IL266206A (en) 2019-06-30
AU2017348175B2 (en) 2021-08-26
AU2017348172A1 (en) 2019-04-18
MX2023005465A (es) 2023-05-22
EP3532092B1 (en) 2026-04-29
JP2019534281A (ja) 2019-11-28
CL2019001129A1 (es) 2019-07-05
IL314808B1 (en) 2026-04-01
US11732019B2 (en) 2023-08-22
SMT202100647T1 (it) 2022-01-10
ES3025907T3 (en) 2025-06-10
US20200385439A1 (en) 2020-12-10
JP7387431B2 (ja) 2023-11-28
US20250026803A1 (en) 2025-01-23
US20210206822A1 (en) 2021-07-08
SA519401646B1 (ar) 2021-12-26
EP3534928A1 (en) 2019-09-11
CN110099692B (zh) 2024-03-12
JP2025131599A (ja) 2025-09-09
KR102573684B1 (ko) 2023-09-04
US10787495B2 (en) 2020-09-29
MA46665B1 (fr) 2021-09-30
KR20190072615A (ko) 2019-06-25
CA3041674A1 (en) 2018-05-03
CN109890410A (zh) 2019-06-14
NI201900043A (es) 2019-10-25
EP3532486B1 (en) 2021-09-22
IL314808A (en) 2024-10-01
LT3532486T (lt) 2021-11-10
US20230365644A1 (en) 2023-11-16
IL266202B2 (en) 2023-09-01
US10961293B2 (en) 2021-03-30
US20190367577A1 (en) 2019-12-05
SA519401647B1 (ar) 2022-01-26
KR20230129194A (ko) 2023-09-06
NZ793477A (en) 2025-09-26
CY1124732T1 (el) 2022-07-22
JOP20190097A1 (ar) 2019-04-28
TWI794189B (zh) 2023-03-01
US20180127476A1 (en) 2018-05-10
IL314808B2 (en) 2026-08-01
JOP20190095A1 (ar) 2019-04-28
KR102653381B1 (ko) 2024-04-02
ECSP19029835A (es) 2019-05-31
EP3532092A1 (en) 2019-09-04
JOP20190096A1 (ar) 2019-04-28
JP2020510606A (ja) 2020-04-09
IL301843B2 (en) 2026-01-01
UY37455A (es) 2018-04-30
PE20190917A1 (es) 2019-06-26
CR20190210A (es) 2019-05-27
ECSP19029942A (es) 2019-05-31
MX2019004955A (es) 2019-06-24
EP3532486A1 (en) 2019-09-04
DOP2019000107A (es) 2019-09-30
NZ752396A (en) 2025-12-19
DOP2019000178A (es) 2020-02-16
CA3041046A1 (en) 2018-05-03
IL301843A (en) 2023-06-01
AU2021269420B2 (en) 2023-11-23
JP2025102780A (ja) 2025-07-08
CR20190208A (es) 2019-05-27
US20200283491A1 (en) 2020-09-10
ECSP19029995A (es) 2019-05-31
PH12019500749A1 (en) 2019-11-11
US11591379B2 (en) 2023-02-28
EP3988123B1 (en) 2025-02-26
EP3532486A4 (en) 2020-06-24
IL301843B1 (en) 2025-09-01
MX2019004952A (es) 2019-06-24
US20210094998A1 (en) 2021-04-01
PE20191079A1 (es) 2019-08-20

Similar Documents

Publication Publication Date Title
AU2022200089B2 (en) Cyclic peptide tyrosine tyrosine compounds as modulators of Neuropeptide Y receptors
EP3784692B1 (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
US9023986B2 (en) Glucose-dependent insulinotropic peptide analogs
EA020326B1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
CN120603839A (zh) Nmu受体2激动剂
US20240117000A1 (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
EA045724B1 (ru) Циклические пептидные тирозин–тирозиновые соединения в качестве модуляторов рецепторов нейропептида y
HK40045710B (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
HK40045710A (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: JANSSEN PHARMACEUTICA NV

Free format text: FORMER NAME(S): JANSSEN PHARMACEUTICA NV; MARK MACIELAG

FGA Letters patent sealed or granted (standard patent)